Q32 Bio Inc. - 8-K Filing

Q32 Bio reports Q3 2026 net loss of $8.9 million and announces bempikibart clinical data showing 40% SALT-20 response at Week 36. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $QTTB

Read the full article at SEC EDGAR

More Regulatory news